---
title: "Ipsen S.A. Non-GAAP EPS of €10.27, revenue of €3.4B; initiates FY25 outlook"
date: "2025-02-13 09:58:08"
summary: "Ipsen S.A. press release (OTCPK:IPSEY): FY Non-GAAP EPS of €10.27. Revenue of €3.4B (+8.6% Y/Y). FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total sales. Financial guidance for 2025 including total sales growth greater than 5.0% at CER, and core..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Ipsen S.A. [press release](https://seekingalpha.com/pr/20000956-ipsen-delivers-solid-results-in-2024-driven-by-strong-performance-across-all-therapeutic) ([OTCPK:IPSEY](https://seekingalpha.com/symbol/IPSEY "Ipsen S.A.")): FY Non-GAAP EPS of €10.27.
* Revenue of €3.4B (+8.6% Y/Y).
* FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total sales.
* Financial guidance for 2025 including total sales growth greater than 5.0% at CER, and core operating margin greater than 30.0% of total sales, based on accelerated sales growth of the ex-Somatuline portfolio and assuming negative impact on Somatuline sales due to increased generic competition in the U.S. and Europe.

More on Ipsen S.A.:
-------------------

* [Historical earnings data for Ipsen S.A.](https://seekingalpha.com/symbol/IPSEF/earnings)
* [Dividend scorecard for Ipsen S.A.](https://seekingalpha.com/symbol/IPSEF/dividends/scorecard)
* [Financial information for Ipsen S.A.](https://seekingalpha.com/symbol/IPSEF/income-statement)

[seekalpha](https://seekingalpha.com/news/4407434-ipsen-sa-non-gaap-eps-of-1027-revenue-of-34b-initiates-fy25-outlook)
